Founded in 2009, the Lung Cancer Mutation Consortium (LCMC), is an association of US cancer centers that facilitates clinical trials designed to change the practice of thoracic oncology. The consortium has conducted trials with thousands of lung cancer patients on topics including genomic testing and, more recently, neoadjuvant treatments. These studies, conducted in collaboration with multiple pharmaceutical sponsors, have led to major changes in guidelines for biomarker testing.
Today’s work is focused on expanding neoadjuvant trials to individuals with molecular alterations and to continue evaluating new biomarkers and therapies in the preoperative setting.
The Lung Cancer Research Foundation serves as the umbrella organization to coordinate LCMC activities and facilitate connections with the advocacy and broader thoracic oncology communities.
Find out more about the current study at ClinicalTrials.gov.
Click on a pin below to learn more about a participating center near you.